leadf
logo-loader
viewTodos Medical Ltd.

Todos Medical announces completion of instrument validation in its mobile lab division

Integrated Health has fully validated the analytical performance of the ANDis 350 RNA auto-extraction machine in combination with its Accurate 96 qPCR machine as part of COVID-19 RT-PCR lab testing validation

Todos Medical Ltd. - Todos Medical announces the completion of the instrument validation in its mobile lab division
Integrated Health is expected to complete the clinical validation needed to support the commercial launch in mid-November

Todos Medical Ltd (OTCQB:TOMDF) announced Monday the completion of the instrument validation in its mobile lab division. 

The company said its mobile CLIA lab partner Integrated Health has fully validated the analytical performance of its proprietary ANDis 350 RNA auto-extraction machine in combination with its Accurate 96 qPCR machine as part of the COVID-19 RT-PCR laboratory testing validation process being performed in MOTO+PARA’s Mobile High Complexity Lab. 

Integrated Health is expected to complete the clinical validation needed to support the commercial launch in mid-November. MOTO+PARA is in talks with several entities and expects to begin accepting contracts in mid-November 2020, Todos said.

READ: Todos Medical strikes deal with Adial Pharmaceuticals to market Assure/FaStep and EcoStep COVID-19 antibody tests

“We have spent the last three months building the mobile labs system in preparation for a commercial launch with a focus on the highest quality, consistent data generation, and overcoming the many technical challenges that presented themselves in the creation of a highly scalable Biosafety Level 3 built mobile lab,” said Eric Canonico, CEO of MOTOPARA Foundation. “We are pleased to have these high levels of analytical performance in the Todos instruments.”

Brandon Albin, managing partner at Integrated Health, added: “We are confident we can commercially launch the COVID-19 qPCR assay using Todos’ testing paradigm and reach a capacity of 1,000 PCR tests per day per mobile unit, in addition to antigen and antibody testing.”

Todos CEO Gerald Commissiong said that having the ability to reduce PCR turnaround times from 3-6 days to potentially as little as 3-6 hours is a “complete game-changer” in terms of speed to diagnosis and reducing time to isolation.

“We will also be offering COVID-19 antigen screening and surveillance testing, as well as antibody testing to our laboratory and delivery of care partners,” he said. 

Currently, Todos said that Integrated Health is in the process of testing 30 known positive and 30 known negative samples to receive CLIA certification allowing MOTO+PARA High Complexity Mobile Labs to operate under Integrated Health’s US national mobile CLIA lab license, authorized in all 50 states. The companies expect to reach this milestone in mid-November.

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Todos Medical Ltd.

Price: 0.055 USD

OTCQB:TOMDF
Market: OTCQB
Market Cap: $11.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Todos Medical reveals positive clinical proof of concept data from its rapid...

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the group has “positive clinical proof of concept data” from its lab-based rapid SARS-CoV-2 3CL protease diagnostic test in collaboration with its joint venture partner NLC Pharma. Commissiong says now, the group is...

1 week, 3 days ago

2 min read